Edge of Yesterday: A 3-part podcast series by ViiV Healthcare

Image of cell phone featuring Edge of Yesterday podcast graphic Image of cell phone featuring Edge of Yesterday podcast graphic

Interviews With Pioneers in AIDS Treatment

Edge of Yesterday, a podcast series, takes you on a journey from the early days of the AIDS epidemic up to the present day. Reflecting on the many milestones along the way reminds us of a subset of patients still in need. Each episode covers an important topic with firsthand accounts.


A Window to the Past

Dr. Michael Gottlieb and virologist Marty St. Clair

Go back to the beginning with two early pioneers in AIDS treatment and research. They talk about their involvement in the development and impact of early HIV-1 treatment. They also discuss their points of view on RUKOBIA, an option for heavily treatment-experienced patients living with HIV-1.

Featured guests

Dr. Gottlieb was responsible for describing the syndrome of opportunistic infections in CD4+ T-cell deficiency that characterized the condition that later became known as AIDS. Dr. Gottlieb also authored the first report of the syndrome to the Centers for Disease Control and Prevention, which was published on June 5, 1981, in Morbidity and Mortality Weekly Report, and would later write about a set of AIDS cases that were published in the New England Journal of Medicine.

Marty St. Clair, a virologist at ViiV Healthcare, has been working as a research scientist since the early 1980s. She was a part of the team that discovered and helped develop the first HIV-1 drug, azidothymidine, otherwise known as AZT, or zidovudine.

View references

“I think it is an important message to patients that the work goes on. People are still looking for options…There is ongoing drug development in the HIV-1 sector and that should give people hope, especially those patients that are no longer responding to the current crop of medicines.”

—Dr. Michael Gottlieb


Who Are Patients With MDR HIV-1?

Dr. Frank Spinelli and RUKOBIA patient Dennis

Dr. Frank Spinelli is ViiV Healthcare's former US Medical Director of Patient Affairs. Hear him talk about heavily treatment-experienced patients, what makes them unique, their treatment priorities, and the RUKOBIA BRIGHTE trial. Dennis, a BRIGHTE trial participant, shares his experiences of living with HIV-1 for three decades and using RUKOBIA as part of his treatment regimen.

Featured guest

Dennis, who is living with HIV-1 and taking RUKOBIA as a part of his HIV-1 treatment regimen, participated in the RUKOBIA BRIGHTE trial. He was diagnosed with HIV-1 in 1991 and is considered a heavily treatment-experienced person living with HIV-1. In the early 2000s, Dennis started working in the field of HIV-1 as a case manager.

View references

“Every 3 months going in and getting that result, ‘well, you’re undetectable,’ kept me going…It just made it all worthwhile.”

—Dennis, BRIGHTE trial participant


A Turning Point for Patients

Dr. Peter Ackerman and Dr. Cathy Creticos

In this interview with Dr. Peter Ackerman, former Physician Project Lead at ViiV Healthcare, and Dr. Cathy Creticos, a clinical investigator on the BRIGHTE trial, discover more about RUKOBIA’s journey from the drug development of fostemsavir, marketed as RUKOBIA, to the BRIGHTE trial.

Featured guest

Dr. Cathy Creticos is an infectious disease specialist and practicing physician. She started working in HIV-1 care in 1985 as a fellow in infectious disease when her site was selected to test azidothymidine, or AZT, the very first drug for HIV-1 treatment. Since then, Dr. Creticos has been in private practice, taking care of patients living with HIV-1. 
In recent years, Dr. Creticos’ clinic was one of the sites selected to participate in the RUKOBIA BRIGHTE trial.

View references

“When RUKOBIA was available through clinical trial, they were extremely excited…This was definitely a beacon of hope for patients who had been heavily treatment experienced and were waiting for a treatment option.”

—Dr. Cathy Creticos


  1. Treating HIV: building on 30 years of innovation, ingenuity and passion. ViiV Healthcare. https://viivhealthcare.com/en-gb/our-stories/our-people/treating-hiv-building-on-30-years-of-innovation-ingenuity-and-passion
  2. Gottlieb MS. AIDS—past and future. N Engl J Med. 2001;344(23):1788-1791. doi:10.1056/NEJM200106073442312
  3. Curran JW, Jaffe HW; Centers for Disease Control and Prevention (CDC). AIDS: the early years and CDC’s Response. MMWR Suppl. 2011;60(04):64-69.
  4. Fee E, Brown TM. Michael S. Gottlieb and the identification of AIDS. Am J Public Health. 2006;96(6):982-983. doi:10.2105/AJPH.2006.088435
  5. Antiretroviral Drug Discovery and Development. National Institute of Allergy and Infectious Diseases. Accessed June 1, 2021. https://www.niaid.nih.gov/diseases-conditions/antiretroviral-drug-development
  6. In Their Own Words… NIH Researchers Recall the Early Years of AIDS. Discovery of HIV. National Institutes of Health (NIH). Department of Health and Human Services. Accessed June 1, 2021. https://history.nih.gov/display/history/Discovery+of+HIV
  7. Shampo MA, Kyle RA. Luc Montagnier—discoverer of the AIDS virus. Mayo Clin Proc. 2002;77(6):506. doi:10.4065/77.6.506
  8. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Department of Health and Human Services. Updated May 26, 2020. Accessed June 1, 2020. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf
  9. Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primers. 2015;1(15035):1-22. doi:10.1038/nrdp.2015.35
  10. In Their Own Words… NIH Researchers Recall the Early Years of AIDS. First Encounters. National Institutes of Health (NIH). Department of Health and Human Services. Accessed June 1, 2021. https://history.nih.gov/display/history/First+Encounters
  11. Centers for Disease Control and Prevention (CDC). Pneumocystis pneumonia—Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):250-252.
  12. Quinn TC. HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS. 2008;22(suppl 3):S7-S12. doi:10.1097/01.aids.0000327510.68503.e8
  13. Cochrane JM. Zidovudine’s patent history. Lancet. 2000;356(9241):1611-1612. doi:10.1016/S0140-6736(05)74463-9
  14. McHugh J. A tap and drain: sinking CD4+ T cells. Nature Milestones. Accessed June 16, 2021. https://media.nature.com/original/magazine-assets/d42859-018-00014-8/d42859-018-00014-8.pdf
  15. Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):e740-e751. doi:10.1016/S2352-3018(20)30240-X
  16. Data on file, ViiV Healthcare.
  17. Cutrell J, Jodlowski T, Bedimo R. The management of treatment-experienced HIV patients (including virologic failure and switches). Ther Adv Infect Dis. 2020(7):1-15. doi:10.1177/2049936120901395
  18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated June 3, 2021. Accessed June 1, 2021. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf